Dexmedetomidine Nasal Spray for the Treatment of Panic Attacks in Adults

StatusCompleted
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Withdrawn → Completed Show 7 more changesShow less
    • Enrollment target: 0 to 40
    • Primary completion date changed from estimate of Aug 30, 2027 to Feb 5, 2026
    • Study completion date changed from estimate of Aug 30, 2028 to Feb 5, 2026
    • Start date changed from estimate of Sep 1, 2025 to Jun 26, 2025
    • Study description revised
    • Collaborators shortened, about 16 words
    • Eligibility criteria expanded, about 2 words
  2. Trial status: Not Yet Recruiting to Withdrawn Sponsor's reason: The study was terminated due to a strategic prioritization and realignment of the research and development portfolio by the study team.
    • Lead sponsor: Yuan Shen to Tongji University
    • Enrollment target: estimated 400 to confirmed 0
    • Collaborators: 1 to 2
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Tongji University
13 trials monitored
See all monitored trials
Anxiety
3,284 trials monitored
See 154 trials at risk
Panic attacks affect 13.2% of adults globally, with acute treatments (e.g., benzodiazepines) carrying dependency risks. Dexmedetomidine, an α₂-adrenergic agonist, achieves peak plasma levels in 5-15 min via nasal delivery and may offer rapid, non-invasive relief for acute panic attacks. Despite preclinical evidence of anxiolytic effects, no randomized trials have evaluated its efficacy for panic attacks.
Trial Details
NCT Number NCT07162649
Lead Sponsor Tongji University
Conditions
(from sponsor)		 Dexmedetomidine, Panic Attacks
Related terms Panic Disorder
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov